Cogent Biosciences (COGT) – Hot Comments
-
Baird Starts Cogent (COGT) at Outperform, Says '$16/share of our $20 price target to bezuclastinib for non-advanced SM'
-
SVB Leerink Reiterates Outperform Rating on Cogent (COGT), 'We believe that the bezuclastinib dataset will be a meaningful catalyst for shares'
-
Back to COGT Stock Lookup